Esther Latres, Ph.D., is director of research at JDRF. In this role, she leads the strategic development of beta cell replacement therapies, and the translation of scientific discoveries into novel therapies for improving glucose and overall metabolic control, which will contribute to better treatments and a cure for type 1 diabetes. Her program identifies and oversees collaborations and investment opportunities in academia and industry related to beta cell replacement. Program priorities include the generation of renewable beta cell sources, optimization of technologies to protect such cells after implantation, and support proof of concept trials to test the safety and efficacy of beta cell replacement therapies.
Prior to joining JDRF in 2015, Dr. Latres was a scientist at Regeneron Pharmaceuticals, where she led discovery and research of drug candidates to treat skeletal muscle and metabolic diseases, some of which have advanced into clinical programs. She is the author on numerous research publications and is the co-inventor on several patents. Esther received a Ph.D. in biochemistry and molecular biology at the University of Barcelona, and has received postdoctoral training and held research positions at Sloan-Kettering Cancer Center, Bristol-Myers Squibb Institute and New York University Medical Center.